Table 3.
A list of selected nHLA antibodies and gene in transplantation.
| nHLA antibody (nHLA-ab) | Organ | Associated factors | Reference |
|---|---|---|---|
| Anti-protein kinase C zeta (PKCf) ab | Kidney | Graft loss | (188) |
| Steroid-resistant rejection and the hypertension | |||
| Mononuclear cell infiltrate of acute rejection | |||
| Anti-MHC I-related chain A (MICA) ab | Kidney | Poor graft survival with only MICA and significantly poor with both antibodies(MICA+/HLA+) | (189–197) |
| Kidney | Preformed MICA antibodies contributes to increasing frequency of graft loss | ||
| Kidney | Chronic rejection, poor graft survival | ||
| Kidney | Graft rejection, poor 1-year graft survival | ||
| Kidney | Poor graft survival | ||
| Heart | The incidence of transplant coronary artery disease | ||
| Heart | No negative effect on graft survival | ||
| Liver | Late graft rejection | ||
| Anti-angiotensin II type I receptor (AT1R) ab | Kidney | Refractory vascular rejection | (198–201) |
| Kidney | Cronic kidney disease | ||
| Kidney | Graft injury, graft loss | ||
| heart | Cellular and Ab-mediated rejection and early onset of microvasculopathy | ||
| Anti-endothelial antibodies (AECA) | Kidney | Cellular rejection | (177, 202–206) |
| Kidney | Hyperacute rejection | ||
| Kidney | Graft rejection | ||
| Kidney | Acute rejection | ||
| Kidney | Microvascular damage | ||
| Heart | Early acute rejection | ||
| Anti-endothelial-1 type A receptor (ETAR) ab | Kidney | Hyperacute rejection | (199, 207) |
| Kidney | Poor graft function early after transplant, hyperacute rejection | ||
| Kidney | Graft injury, graft loss | ||
| Heart | Cellular and Ab-mediated rejection and early onset of microvasculopathy | ||
| Anti-peroxisomal-trans-2-enoyl-coA-reductase (PECR) ab | Kidney | Transplant glomerulopathy | (79, 208) |
| Anti-PRKRIP1ab | Kidney | Cronic kidney disease | (32, 208) |
| Antivimentin ab | Heart | It did not correlate with early post-transplant rejection or graft survival | (32) |
| Non-HLA pigmy ab | Heart | Mortality | (209) |
| Antibodies against | Kidney | Acute ABMR | (210) |
| Endoglin | |||
| Epidermal growth factor (EGF)-like repeats | |||
| Discoidin I-like domains 3 | |||
| Intercellular adhesion molecule 4 | |||
| FMS-like tyrosine kinase-3 ligand | |||
| Antibodies against | Kidney | Chronic allograft injury (CAI) | (26) |
| MIG | |||
| ITAC | |||
| IFN-c | |||
| Glial-derived neurotrophic factor (GDNF) | |||
| Collagen type V, K-α1-tubulin | Lung | Graft disfunction, bronchiolitis obliterans syndrome | (207) |
| nHLA gene | |||
| FN-γ, IL-1B, IL-1RN, IL-2, IL-6, IL-7, IL-17, CCR9, ESR1, FAS Stem cell | GVHD ↑ | (206) | |
| IL-10, NOD2, toll-like receptors | GVHD ↑ or GVHD ↓ | ||
| VDR | GVHD ↑, mortality ↑ | ||
| CTLA4 | Acute GVHD ↑, survival ↑ | ||
| IL-7R, CXCL10 | Transplant-related mortality ↑ | ||
| IL-18 | Transplant-related mortality ↓ | ||
| Il-23R | Acute GVHD ↓ | ||
| HLA-E | Chronic GVHD ↓ | ||
| IL-1A | Chronic and acute GVHD ↑, transplant-related mortality ↑ | ||
| CCl-2 | Over roll survival ↓, transplant-related mortality ↑ | ||
| CXCL12 | Hematological recovery ↑ | ||
| TGFβ | Acute GVHD ↓, over roll survival ↓ | ||
| HMGB1 | Relapse ↑, relapse-related mortality ↑, transplant-related mortality ↑, over roll survival ↑, acute GVHD ↓, chronic GVHD ↑ | ||
| MICA | GVHD ↑ |